STOCK TITAN
  1. Home
  2. News
  3. KURA

Kura Oncology Inc Stock Price, News & Analysis

KURA Nasdaq

Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.

Kura Oncology, Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company advancing precision therapies for genetically defined cancers. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's innovative pipeline, including its lead menin inhibitor ziftomenib for acute myeloid leukemia (AML).

Access authoritative updates on clinical trial progress, regulatory milestones, and strategic collaborations. Our curated collection features official press releases, financial disclosures, and scientific presentations - all organized for efficient tracking of Kura's developments in targeted cancer treatment.

Key content categories include clinical trial results, FDA communications, research partnerships, and quarterly financial reports. The repository serves as a reliable resource for understanding Kura's position in precision oncology and its approach to addressing high-need cancer populations.

Bookmark this page for direct access to Kura Oncology's verified announcements. For comprehensive analysis of these developments, consult your financial advisor and review SEC filings in conjunction with these updates.

News

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on precision cancer medicines, has announced inducement grants to eight new employees. The Compensation Committee approved nonstatutory stock options to purchase 141,750 shares of common stock under the company's 2023 Inducement Option Plan.

The stock options have an exercise price of $5.60 per share, based on the closing price on July 1, 2025. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, contingent on continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
none
-
News

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Rhea-AI Summary
Kura Oncology and Kyowa Kirin reported positive Phase 1a/1b trial results for ziftomenib combined with 7+3 chemotherapy in newly diagnosed AML patients. The KOMET-007 trial showed impressive complete remission rates of 93% in NPM1-mutant and 89% in KMT2A-rearranged AML patients. Notable MRD-negativity rates were achieved: 71% in NPM1-m and 88% in KMT2A-r patients. The treatment demonstrated favorable safety with no additive myelosuppression. High survival rates were observed with 96% of NPM1-m and 88% of KMT2A-r patients remaining alive and on study. Phase 3 studies (KOMET-017-IC and NIC) are planned to start in second half of 2025. The data suggests ziftomenib's potential as a frontline treatment option for AML patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
-
News

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Kura Oncology (NASDAQ: KURA) announced the granting of inducement awards to five new employees on June 2, 2025. The awards consist of nonstatutory stock options to purchase 79,200 shares of common stock under the Company's 2023 Inducement Option Plan. The stock options have an exercise price of $6.30 per share, matching the company's closing price on the grant date. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved by the Compensation Committee as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
News

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Rhea-AI Summary
Kura Oncology and Kyowa Kirin presented positive pivotal Phase 2 trial results for ziftomenib, their oral menin inhibitor, in treating relapsed/refractory NPM1-mutated AML patients. The drug achieved a 23% CR/CRh rate (21/92 patients) with 63% of evaluable responders achieving MRD-negative status. The treatment showed consistent efficacy across subgroups and demonstrated a favorable safety profile with only 3% discontinuation rate due to treatment-related adverse events. Notably, responders showed a median overall survival of 16.4 months compared to 3.5 months for non-responders. With a PDUFA date of November 30, 2025, ziftomenib could become the first FDA-approved therapy specifically for NPM1-mutated AML, which represents approximately 30% of AML cases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
none
-
News

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Rhea-AI Summary
The FDA has accepted Kura Oncology and Kyowa Kirin's New Drug Application (NDA) for ziftomenib, granting Priority Review for treating adult patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). The PDUFA target action date is set for November 30, 2025. The NDA is supported by positive results from the Phase 2 KOMET-001 trial, which met its primary endpoint of complete remission plus CR with partial hematological recovery. Ziftomenib demonstrated a favorable safety profile with limited myelosuppression and only 3% treatment-related discontinuations. The drug has received multiple FDA designations including Breakthrough Therapy, Fast Track, and Orphan Drug. If approved, ziftomenib would be the first menin inhibitor for treating this aggressive form of AML.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.72%
Tags
clinical trial fda approval
-
News

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

Rhea-AI Summary
Kura Oncology and Kyowa Kirin announced that data from their KOMET-001 registration-directed trial of ziftomenib will be presented at the 2025 ASCO Annual Meeting. Ziftomenib, a daily oral menin inhibitor, is being evaluated for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML). The drug achieved its primary endpoint of complete remission plus CR with partial hematological recovery, with statistical significance. Notably, ziftomenib is the only investigational therapy to receive Breakthrough Therapy Designation from the FDA for this indication. The treatment showed promising results with limited myelosuppression and only 3% treatment-related discontinuations. NPM1 mutations represent approximately 30% of AML cases, with no FDA-approved therapies currently available. The detailed results will be presented on June 2nd, 2025, followed by a virtual investor event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.62%
Tags
none
News

Kura Oncology to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, has announced its participation in three major upcoming investor conferences in May and June 2025:

  • TD Cowen 6th Annual Oncology Innovation Summit (Virtual) - May 27, 2025, at 9:00 a.m. ET
  • Jefferies Global Healthcare Conference (NYC) - June 4, 2025, at 2:35 p.m. ET
  • Goldman Sachs Annual Global Healthcare Conference (Miami) - June 10, 2025, at 11:20 a.m. ET

Live webcasts will be available on Kura's website with archived replays accessible after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
-
News

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Rhea-AI Summary
Kura Oncology (NASDAQ: KURA) and Kyowa Kirin announced that data from their KOMET-007 trial of ziftomenib will be presented at the 2025 European Hematology Association Congress in Milan. The presentation will focus on clinical data from combining ziftomenib, an oral menin inhibitor, with standard chemotherapy (7+3) in newly diagnosed NPM1-mutant and KMT2A-rearranged acute myeloid leukemia (AML) patients. The data comes from Phase 1a dose-escalation and Phase 1b dose-expansion portions of the trial. Two additional abstracts for the KOMET-001 and KOMET-017 trials will also be presented. Dr. Mollie Leoni, Chief Medical Officer of Kura Oncology, expressed confidence in ziftomenib's potential as a treatment option for AML patients when combined with intensive chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
News

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

Rhea-AI Summary

Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Bank of America Securities 2025 Healthcare Conference. The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a fireside chat on May 13, 2025, at 6:00 p.m. ET / 3:00 p.m. PT. Investors can access a live audio webcast of the presentation through Kura's website, with a replay available afterward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.84%
Tags
conferences
News

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Kura Oncology (NASDAQ: KURA) announced that its Compensation Committee granted inducement awards to 16 new employees on May 1, 2025. The awards consist of nonstatutory stock options to purchase 433,950 shares of common stock under the Company's 2023 Inducement Option Plan. The stock options have an exercise price of $6.49 per share, matching the company's closing price on May 1, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none

FAQ

What is the current stock price of Kura Oncology (KURA)?

The current stock price of Kura Oncology (KURA) is $5.86 as of July 3, 2025.

What is the market cap of Kura Oncology (KURA)?

The market cap of Kura Oncology (KURA) is approximately 496.1M.
Stock KURA logo
Kura Oncology Inc

Nasdaq:KURA

KURA Rankings

#4059 Ranked by Market Cap
N/A Ranked by Dividends

KURA Stock Data

496.07M
84.44M
1.15%
102.19%
11.41%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO